NCT07503756 JS-212 Metastatic Colorectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07503756 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 26 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07503756 is a hot trial to watch
Metastatic Colorectal Carcinoma is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07503756 is notable because it evaluates JS-212 in a Phase 2 design sponsored by Shanghai Junshi Biosciences Co., Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07503756 |
| Official title | JS212 Combination Therapies in Metastatic Colorectal Cancer |
| Phase / status | Phase 2 / Recruiting |
| Intervention | JS-212 |
| Sponsor | Shanghai Junshi Biosciences Co., Ltd. |
| Geography | China |
| Enrollment | not reported |
| Primary endpoint | Investigator-assessed objective response rate (ORR) |
| Endpoint time frame | Up to approximately 12 months |
| Primary completion / readout proxy | not reported |
Protocol design and endpoint interpretation
This is an open-label, multicenter Phase 2 clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JS212-based combination therapies in patients with metastatic colorectal cancer (mCRC). JS212 is a bispecific antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) and HER3 with a topoisomerase I inhibitor payload. Preclinical and early clinical data suggest that dual targeting of EGFR and HER3 may enhance antitumor activity and overcome resistance mechanisms associated with EGFR- or HER2-directed therapies. This study will investigate JS212 in combination with capecitabine, with or without Bevacizumab, and JS212 in combination with chemotherapy (XELOX: capecitabine and oxaliplatin), with or without the PD-1/VEGF bispecific antibody JS207, in patients with mCRC. The study will assess safety, determine the recommended Phase 3 dose (RP3D), and evaluate preliminary
Allocation is Non-Randomized, masking is Single, and the intervention model is Parallel Assignment. Planned enrollment was not reported; study geography in China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Investigator-assessed objective response rate (ORR)(Up to approximately 12 months) — Proportion of participants with confirmed complete response (CR) or partial response (PR) according to RECIST v1.1.
- Safety and Tolerability(AEs)(From first dose up to approximately 90 days after last dose) — Incidence and severity of adverse events (AEs) assessed according to CTCAE.
- Safety and Tolerability(SAEs)(From first dose up to approximately 90 days after last dose) — Incidence and severity of serious adverse events (SAEs)assessed according to CTCAE.
- Safety and Tolerability(DLTs)(From first dose up to approximately 90 days after last dose) — Incidence and severity dose-limiting toxicities (DLTs) assessed according to CTCAE.
Readout outlook and evidence gap
The current protocol points to not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor:connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: JS-212 is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: Shanghai Junshi Biosciences Co., Ltd. is resolved to a normalized organization record in Shanghai Shi, China. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07503756 provides a focused lens on Metastatic Colorectal Carcinoma development. Its value will be determined by whether JS-212 can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis?Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
